New York, August 24th 2018 — As a valuable partner focused on antibody-drug conjugates (ADCs) research and development, Creative Biolabs recently launched a powerful ADC payload called amatoxin based on their exclusive “DrugLnk” organic synthesis platform.
Antibody-drug conjugates (ADCs) are next-generation targeted anti-tumor agents, consisting of a monoclonal antibody with a cytotoxic payload drug via a small molecular linker. The toxic payload drug as an essential component of any therapeutic ADC plays a decisive role in determining its efficacy.
“In reality, not every toxin is suitable to be used as an ADC payload. To serve this very purpose, the toxins must exert extremely high cytotoxic efficacy and adequate plasma stability with a small size to minimize the risk of immunogenicity. Since current ADC strategies rely on the internalization of the toxin conjugates, the targets of the payloads must be located inside the cell.” Said a scientist from Creative Biolabs.
“Based on these criteria, amatoxins, a group of toxic compounds produced by green and white Amanita muscaria that result in fatal human Amanita intoxications upon ingestion, are synthesized via the cleavage, modification, and cyclization of precursor peptides that usually contain a ~10 amino acid-residue leader peptide followed by the amatoxin peptide and a recognition sequence. They are not only powerful inhibitors of gene transcription and preferentially target RNA polymerase II, a crucial enzyme in mRNA biosynthesis, but also promising toxic payloads in ADC developments based on their specific MOA and high water solubility, showing good efficacy against pancreatic carcinomas and some other EpCAM-expressing malignancies.”
Scientists in Creative Biolabs are highly experienced in full chemical synthesis, chemical modification, as well as bio-conjugation, dedicated to helping our clients prepare innovated payload-linker complexes for novel ADC developments.
About Creative Biolabs
Established in 2004, Creative Biolabs is highly specialized in advanced antibody biochemistry and engineering. With more than a decade of exploration and expansion, our current research and service capacity covers the entire new drug discovery and development pipeline, ranging from early discovery, pre-clinical evaluations, cGMP manufacturing, to clinical trials. As an international cooperation, we have established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with our customers and research partners to develop new medicines for a better, healthier world.
Media Contact
Company Name: Creative Biolabs
Contact Person: Bella Smith
Email: Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States
Website: https://www.creative-biolabs.com/adc/